CLINICAL TRIALS PROFILE FOR ELAVIL

All Clinical Trials for ELAVIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000428 ↗	Combining N-of-1 Trials to Assess Fibromyalgia Treatments	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 4	2000-09-01	This study will compare the effectiveness of combination therapy with the drugs amitriptyline and fluoxetine (AM+FL) and amitriptyline (AM) alone in the treatment of people with fibromyalgia. Doctors will treat each study participant with both AM + FL and AM alone for 6 weeks at a time. The study uses a method that combines results from treatment of individual patients to assess overall treatment effectiveness and help individual patients and their physicians with their treatment decisions. This study will also help compare the results of community-based studies (studies involving private doctors) and studies based at clinical research centers.
NCT00000428 ↗	Combining N-of-1 Trials to Assess Fibromyalgia Treatments	Completed	Tufts Medical Center	Phase 4	2000-09-01	This study will compare the effectiveness of combination therapy with the drugs amitriptyline and fluoxetine (AM+FL) and amitriptyline (AM) alone in the treatment of people with fibromyalgia. Doctors will treat each study participant with both AM + FL and AM alone for 6 weeks at a time. The study uses a method that combines results from treatment of individual patients to assess overall treatment effectiveness and help individual patients and their physicians with their treatment decisions. This study will also help compare the results of community-based studies (studies involving private doctors) and studies based at clinical research centers.
NCT00248651 ↗	Functional Dyspepsia Treatment Trial	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2/Phase 3	2006-10-01	Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.
NCT00248651 ↗	Functional Dyspepsia Treatment Trial	Completed	Mayo Clinic	Phase 2/Phase 3	2006-10-01	Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.
NCT00862095 ↗	Medical Therapies for Chronic Post-Traumatic Headaches	Terminated	U.S. Army Medical Research and Development Command	Phase 4	2008-06-01	To determine if propranolol, amitriptyline, or topiramate decreases headache frequency in patients with chronic post-traumatic headaches.
NCT00862095 ↗	Medical Therapies for Chronic Post-Traumatic Headaches	Terminated	U.S. Army Medical Research and Materiel Command	Phase 4	2008-06-01	To determine if propranolol, amitriptyline, or topiramate decreases headache frequency in patients with chronic post-traumatic headaches.
NCT00862095 ↗	Medical Therapies for Chronic Post-Traumatic Headaches	Terminated	Madigan Army Medical Center	Phase 4	2008-06-01	To determine if propranolol, amitriptyline, or topiramate decreases headache frequency in patients with chronic post-traumatic headaches.

Clinical Trial Conditions for ELAVIL

Condition Name

Condition Name for ELAVIL
Intervention	Trials
Headache	2
Autism Spectrum Disorder	1
Migraine	1
Brain Injuries	1

Condition MeSH

Condition MeSH for ELAVIL
Intervention	Trials
Headache	4
Post-Traumatic Headache	2
Migraine Disorders	2
Child Development Disorders, Pervasive	1

Clinical Trial Locations for ELAVIL

Trials by Country

Trials by Country for ELAVIL
Location	Trials
United States	14
Iran, Islamic Republic of	1
Canada	1
Ghana	1

Trials by US State

Trials by US State for ELAVIL
Location	Trials
Washington	2
Massachusetts	2
Ohio	1
New York	1
New Jersey	1

Clinical Trial Progress for ELAVIL

Clinical Trial Phase

Clinical Trial Phase for ELAVIL
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for ELAVIL
Clinical Trial Phase	Trials
Completed	5
Terminated	2
Unknown status	2

Clinical Trial Sponsors for ELAVIL

Sponsor Name

Sponsor Name for ELAVIL
Sponsor	Trials
Tufts Medical Center	1
American Laryngological Association	1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1

Sponsor Type

Sponsor Type for ELAVIL
Sponsor	Trials
Other	12
NIH	4
U.S. Fed	3

ELAVIL Market Analysis and Financial Projection

Last updated: April 29, 2026

ELAVIL (Amitriptyline): Clinical Trials Update, Market Analysis, and Projection

Is ELAVIL in active clinical trials?

No current, high-enrollment late-stage clinical trial programs for ELAVIL (amitriptyline) are identifiable from the publicly indexed trial record set available at the time of this analysis. ELAVIL is a legacy, off-patent small-molecule antidepressant first approved decades ago, and the trial footprint is typically dominated by:

• observational studies, comparative effectiveness research, and small mechanistic studies
• new formulations or repurposing programs that do not usually support a blockbuster-style late-stage pipeline

Implication for development planning: ELAVIL does not present a conventional “clinical trial update” story driven by pivotal Phase 3 readouts. The competitive value proposition is largely anchored in formulation differentiation, real-world evidence, and payer coverage rather than near-term regulatory risk-taking.

---

What does the market look like for ELAVIL (amitriptyline)?

ELAVIL is a branded form of a widely available generic antidepressant (amitriptyline). Market dynamics follow classic off-patent patterns:

• price compression versus generics
• branded demand tied to formulary preferences, historical prescribing patterns, and prescriber familiarity
• utilization across multiple indications where amitriptyline has established clinical use (most prominently depression and chronic pain syndromes such as neuropathic pain)

Competitive structure

• Direct competition: generic amitriptyline products
• Indirect competition: other antidepressants and pain-modifying agents (TCAs, SNRIs, gabapentinoids, topical analgesics, and newer neuromodulatory options)

Commercial levers that matter most

• formulary position and step-therapy rules
• gross-to-net dynamics from managed care contracting
• substitution policies at the pharmacy counter

---

How does ELAVIL pricing and reimbursement behave in off-patent markets?

In off-patent segments, branded pricing typically targets net revenue resilience rather than list price growth. The principal forces are:

• generic substitution at retail pharmacy
• rebate intensity and class-wide formulary negotiations
• PBM steering toward lower net-cost alternatives

Operationally, branded revenue is most sensitive to:

• the net price gap versus lowest-cost generics
• therapy switching behavior in chronic use populations
• adherence effects in long-duration indications

---

What is the revenue trajectory for ELAVIL over the next 3 to 5 years?

A robust forward projection for ELAVIL brand revenues cannot be stated precisely without current brand-specific sales baselines and segment-level payer mix. What can be stated with market-structure accuracy is the direction:

Projection direction (brand-level):

• Flat to declining revenues for ELAVIL-branded supply in the presence of ongoing generic substitution
• Stabilization only if there is a measurable improvement in formulary position (or contracting that offsets net price erosion)

Projection direction (total amitriptyline category):

• Gradual growth or stable consumption is likely because chronic-use indications support continued prescribing
• growth is driven more by population needs and prescribing persistence than by brand share gains

Key driver stack

1. generic availability and competitive pricing pressure
2. payer utilization management and formulary tiering
3. chronic use persistence and adherence in depression and chronic pain cohorts

---

What clinical evidence landscape should investors track for ELAVIL?

Since ELAVIL is not typically tied to new late-stage pivotal programs, the evidence that can move commercial outcomes is:

• comparative effectiveness against other antidepressants or pain therapies in real-world datasets
• outcomes linked to tolerability and adherence (switching, discontinuation, dose persistence)
• subgroup evidence where TCAs show comparative advantage (for example, mixed depressive disorders with prominent pain features)

The near-term “signal” to monitor is less about FDA labeling expansion and more about:

• guideline updates that reinforce amitriptyline’s clinical positioning
• payer policies that reference outcomes, not just drug class cost

---

Key risks to market share and brand revenues

1) Generic substitution intensity

• increases in generic share pressure branded net pricing

2) Safety and tolerability scrutiny

• anticholinergic burden and cardiotoxicity concerns can shift prescribers toward alternatives in older cohorts

3) Indication drift toward newer alternatives

• newer neuropathic pain and depression therapies can take incremental share even when amitriptyline remains clinically used

---

Key opportunities

1) Managed care contracting that protects net price

• targeted rebates and utilization agreements can preserve brand demand within a generic-dominated environment

2) Formulation differentiation

• any reformulation that reduces side effects or improves adherence can support payer acceptance and reduce switching

3) Evidence-led positioning

• real-world evidence supporting efficacy and adherence can support formulary maintenance

---

Market forecast framework (actionable ranges)

Because brand-specific baseline sales are not provided in the input, this section provides a structure for projection rather than unsupported point estimates.

Brand ELAVIL revenue (3 to 5 year range):

• Likely low single-digit decline per year under steady generic substitution
• Possible flat outcome if contracting offsets net price declines and retention improves

Category amitriptyline volume (3 to 5 year range):

• Likely stable to low growth driven by chronic care persistence and incremental patient starts

Share dynamics:

• Brand share typically decreases unless there is a differentiator that reduces substitution

---

Key Takeaways

• ELAVIL is a legacy, off-patent product; the “clinical trials update” is not shaped by late-stage pivotal readouts and is dominated by smaller real-world and mechanistic studies.
• Brand-level revenues are structurally pressured by generic substitution, with performance governed by gross-to-net, payer formulary status, and adherence persistence.
• The most realistic 3 to 5 year outlook is flat to declining brand revenue with stable to low-growth category consumption, unless contracting or formulation changes protect net price and reduce switching.

---

FAQs

1) What is ELAVIL’s main competitive threat?

Generic amitriptyline substitution and payer steering toward lowest net-cost alternatives in managed care.

2) What drives ELAVIL demand if it is off-patent?

Formulary position, rebate contracting, prescriber familiarity, and adherence in chronic-use cohorts.

3) Does ELAVIL have a meaningful late-stage pipeline?

Publicly indexed late-stage pivotal programs are not the dominant story; the profile is typically smaller comparative effectiveness or mechanistic work.

4) What evidence types matter most for payer decisions?

Real-world effectiveness, persistence, discontinuation, and tolerability-linked adherence outcomes.

5) What would improve ELAVIL’s revenue outlook?

A formulary-protecting net-price strategy, a differentiation in formulation with better tolerability, or guideline/payer support that favors amitriptyline for specific chronic pain or depression subgroups.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Search results for amitriptyline and Elavil (accessed 2026-04-29).
[2] FDA. Drug Approval Reports and labeling information for Elavil (amitriptyline hydrochloride) (accessed 2026-04-29).
[3] IQVIA and other market research databases. Branded versus generic antidepressant market dynamics for off-patent products (accessed 2026-04-29).